Navigation Links
OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
Date:10/19/2010

tion of new cancer therapies that address treatment resistance in cancer patients.  OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen, also referred to as OGX-011.  Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer.  The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 has entered Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.  More information about OncoGenex is available at www.oncogenex.com.

More information about OncoGenex is available at www.oncogenex.com. OncoGenex' Forward Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, OncoGenex' intention to conduct a public offering of common stock and warrants.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements.  These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the ability to manage successfully and complete the public offering, the economic and/or market conditions generally, risks r
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
2. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
3. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
4. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
5. OncoGenex Reports Second Quarter Financial Results
6. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
8. OncoGenex Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
10. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
(Date:7/24/2014)... at the University of Delaware, is known worldwide ... engineering, environmental sustainability and electronics. , His early ... a well-defined, crystalline structure. At the atomic scale, ... zeolites can separate molecules with size differences of ... a nanometer), making them useful to the chemical ...
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... 2014 Deep Research Report on Global ... and in-depth research report on Potassium Sulphate ... information, including its definition, classification, application, and industry ... the international market analysis, including China’s domestic market ... environment & economic situation analysis, the influence of ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4
... Feb. 5 Amicus Therapeutics (Nasdaq: FOLD ) announced ... Crowley as Chairman of the Board in addition to his ... will succeed Donald J. Hayden, Jr. , who will become ... to elect Mr. Crowley as Chairman of the Board reflects our ...
... Science , by researchers at Rothamsted Research (an institute ... Institute, and the Universities of Exeter, Greenwich and York, ... insects to undertake long-distance migrations, and highlights the remarkable ... cold British winters by migrating south in autumn to ...
... 4, 2010 -- Four Oak Ridge National Laboratory researchers ... research grants as part of the Department of Energy,s ... program, funded under the American Recovery and Reinvestment Act ... support exceptional researchers during the crucial early career years, ...
Cached Biology Technology:Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board 2Migrating insects fly in the fast lane 24 ORNL researchers selected for Recovery Act early career funds 24 ORNL researchers selected for Recovery Act early career funds 3
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... species of fish, according to a new study ... tested fish anti-predator behaviour. , Three-spined sticklebacks ... when exposed to additional noise, whereas no effects ... author Dr Irene Voellmy of Bristol,s School of ... environments have increased substantially during the last few ...
(Date:7/24/2014)... A sake brewery has its own microbial terroir, meaning ... resemble those found in the product, creating the final ... the journal Applied and Environmental Microbiology . This ... census of a sake brewery. , Many sake ... author David A. Mills of the University of California, ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4The microbes make the sake brewery 2
... diabetes places a huge burden on its victims and poses ... attacks and stroke cases, but also many other deleterious conditions, ... In Germany alone, some seven million people currently suffer from ... to reach 370 million by the year 2030. Type 2 ...
... A discovery by Monash University scientists could see humble ... ,lab-on-chip, devices capable of detecting diseases such as kidney ... researchers have used ordinary cotton thread and sewing needles ... which is the size of a postage stamp. ...
... may look identicalnot to mention drabto the human eye. But ... are essentially colorblind. A new study published online on February ... reveals that the fish can easily tell one species from ... patterns on their faces. Although scientists have long known ...
Cached Biology News:The pig and its pancreas 2The pig and its pancreas 3How long is a piece of thread? Long enough to save a life 2Fish can recognize a face based on UV pattern alone 2
... Kits without ammonium sulfate are compatible with ... as Taq and AmpliThem™™ DNA polymerases. You ... systems in one experiment by adding your ... the PreMixes supplied with the kit. This ...
... MasterAmp™ PCR Optimization Kits without ammonium sulfate ... in PCR, such as Taq and AmpliThem™™ ... performance of PCR systems in one experiment ... PCR primers into the PreMixes supplied with ...
... Optimization Kits with ammonium sulfate are compatible ... such as Tfl, Tth, and Pfu DNA ... of PCR systems in one experiment by ... primers into the PreMixes supplied with the ...
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
Biology Products: